Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 11—November 2004
International Conference on Women and Infectious Diseases (ICWID)

Rubella Elimination and Improving Health Care for Women

Carlos Castillo-Solórzano* and Jon Kim Andrus*Comments to Author 
Author affiliations: *Pan American Health Organization Washington, DC, USA

Main Article


Rubella and congenital rubella eliminationa,b

Time Country Target group Vaccine used Coverage achieved (%)
1998–2001 English-speaking Caribbean
18 countries 2.16 million men/women 20–29 y MR and MMR Average 80c
Range 64–97
1999 Chile 2.5 million women 10–29 y R 98
2001 Costa Rica 1.6 million men/women 15–39 y MR 98c
2002 Brazil
13 states
11 states 27 million, women 12–39 yd MR 95
2002 Honduras 3.3 million men 5–39 y
women 5–49 y MR 98
Men 95
Women 98
2004 El Salvador 2.8 million men/women 15–39 y MR 99
Men 93
Women 99
2004 Ecuador 4.8 million men/women 16–39 y MR 100
Men 100
Women 100

aCRS, congenital rubella syndrome; R, rubella containing vaccine; MR, double viral vaccine, measles/rubella containing vaccine; MMR, triple viral
bSource: 12–18.
cMen/women vaccinated in equal proportions.
dSome states modified the age of the group based on the year of the vaccine introduction.

Main Article

Page created: May 04, 2011
Page updated: May 04, 2011
Page reviewed: May 04, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.